844500-75-0 Usage
General Description
Methyl (4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbaMate is a chemical compound used in organic synthesis and pharmaceutical research. It is a methyl carbamate derivative containing a boronate ester functionality. Methyl (4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbaMate has potential applications in the development of new drugs and in the synthesis of complex organic molecules. Its unique structure and reactivity make it a valuable building block in the creation of novel chemical compounds with biological activity. Additionally, the boronate ester group in this compound can serve as a site for selective chemical transformations, making it a versatile tool in the field of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 844500-75-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,4,5,0 and 0 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 844500-75:
(8*8)+(7*4)+(6*4)+(5*5)+(4*0)+(3*0)+(2*7)+(1*5)=160
160 % 10 = 0
So 844500-75-0 is a valid CAS Registry Number.
844500-75-0Relevant articles and documents
Outer-sphere direction in iridium C-H borylation
Roosen, Philipp C.,Kallepalli, Venkata A.,Chattopadhyay, Buddhadeb,Singleton, Daniel A.,Maleczka, Robert E.,Smith, Milton R.
supporting information; experimental part, p. 11350 - 11353 (2012/08/29)
The NHBoc group affords ortho selective C-H borylations in arenes and alkenes. Experimental and computational studies support an outer sphere mechanism where the N-H proton hydrogen bonds to a boryl ligand oxygen. The regioselectivities are unique and com
PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS
-
Page/Page column 85-86, (2008/12/08)
The present invention relates to Pyrazolopyrimidine Analogs, methods of making Pyrazolopyrimidine Analogs, compositions comprising a Pyrazolopyrimidine Analog, and methods for treating mTOR-related disorders comprising administering to a subject in need thereof an effective amount of a Pyrazolopyrimidine Analog. The invention also relates to treating PI3K-related disorders comprising administering to a subject in need thereof an effective amount of a Pyrazolopyrimidine Analog.